ImmunisLogoWImmunisLogoImmunis Featured in Lifespan.ioImmunis Featured in Lifespan.io
  • Home
  • About
  • Technology
  • Clinical Trials
  • News & Media
  • Contact
✕
Immunis Announces First-in-Human Injection of Secretome Product for Age-Related Muscle Atrophy
Immunis Chairman Dr. Hans Keirstead to Present at the 2023 Biotech Showcase
Immunis Featured in Lifespan.io
IRVINE, Calif. — January 6, 2023 —

Immunis Inc.‘s press release announcing the first-in-human injection of STEM was highlighted by Lifespan.io, an online news source for breakthrough technologies and scientific discoveries in aging and longevity. The article is entitled “Immunis Begins Clinical Trial of Stem Cell Secretome.” The high-level, scientific content for Lifespan.io is supported by The Lifespan Extension Advocacy Foundation (LEAF), a 501(c)(3) non-profit organization promoting fundamental research on aging and age-related diseases, as well as educating the public on the possibility of preventing age-related diseases.

###

Share

Recent News

  • Jan 26, 2023

    Immunis Chairman Dr. Hans Keirstead to Present at 2023 BIO CEO and Investor Conference

  • Jan 24, 2023

    Immunis Recruits Individuals with Muscle Atrophy for Phase 1/2a Clinical Trial

  • Jan 16, 2023

    Immunis Inc. Featured by DelveInsight for Recent Developments in Knee Osteoarthritis Research

Navigation

  • Home
  • About
  • Technology
  • Clinical Trials
  • News & Media
  • Contact

Contact info

Immunis, Inc.
Irvine, California


contact@immunisbiomedical.com

© 2022 Immunis, Inc. | All Rights Reserved